{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:39:24Z","timestamp":1794296364390,"version":"4.9.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.autrev.2019.102398","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T11:23:25Z","timestamp":1571484205000},"page":"102398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents"],"prefix":"10.1016","volume":"18","author":[{"given":"Andrea","family":"Rubbert-Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda Zsuzsanna","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Kedves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.autrev.2019.102398_bb0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: from biological agents to small molecules","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102398_bb0010","doi-asserted-by":"crossref","first-page":"104340","DOI":"10.1016\/j.phrs.2019.104340","article-title":"The therapeutic journey of biologic agents: there will be an end?","volume":"2","author":"Atzeni","year":"2019","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.autrev.2019.102398_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2017.11.005","article-title":"Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same?","volume":"417","author":"Rubbert-Roth","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2019.102398_bb0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102398_bb0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2011.01.001","article-title":"Switching rheumatoid arthritis treatments: an update","volume":"10","author":"Atzeni","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2019.102398_bb0030","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2011.10.012","article-title":"To switch or not to switch after a poor response to a TNF\u03b1 blocker? It is not only a matter of ACR20 OR ACR50","volume":"11","author":"Buch","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102398_bb0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNFalpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2019.102398_bb0040","first-page":"1","article-title":"Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN registry","author":"Monti","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2019.102398_bb0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","article-title":"The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives","volume":"16","author":"Favalli","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2019.102398_bb0050","first-page":"2156","article-title":"Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry","volume":"54","author":"Jorgensen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2019.102398_bb0055","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss clinical quality management registry","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102398_bb0060","author":"RABBIT Registry"},{"key":"10.1016\/j.autrev.2019.102398_bb0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine."},{"issue":"2","key":"10.1016\/j.autrev.2019.102398_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2019.102398_bb0075","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"57 Suppl 7","key":"10.1016\/j.autrev.2019.102398_bb0080","doi-asserted-by":"crossref","first-page":"vii42","DOI":"10.1093\/rheumatology\/key195","article-title":"Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus","volume":"57","author":"Todoerti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102398_bb0085","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2019.102398_bb0090","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicentre, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2019.102398_bb0095","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2019.102398_bb0100","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with actve rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"67","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9865","key":"10.1016\/j.autrev.2019.102398_bb0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.autrev.2019.102398_bb0115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"10139","key":"10.1016\/j.autrev.2019.102398_bb0120","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2019.102398_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2019.102398_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2019.102398_bb0135","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELARATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2019.102398_bb0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"Harrold","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2019.102398_bb0145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0150","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2019.102398_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/annrheumdis-2016-eular.1605","article-title":"Six years tocilizumab use in patients with rheumatoid arthritis with one previous anti-TNF agent exposure: comparison with adalimumab and etanercept from the provincial electronic database and registry Rhumadata","volume":"75","author":"Bessette","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2019.102398_bb0160","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2019.102398_bb0165","article-title":"Interest of assessing anti-drug antibodies for the choice between a second anti-TNF and a non-TNF targeted biologic in patients with inadequate response to a first anti-TNF: results from the randomized controlled trial \u201cRotation or change\u201d(abstract 3113)","volume":"67","author":"Candon","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102398_bb0170","first-page":"479","article-title":"Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting","volume":"36","author":"Iannazzo","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.102398_bb0175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0180","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0185","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2019.102398_bb0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2003.015933","article-title":"Infliximab treatment for rheumatoid arthritis, with dose titration based on the disease activity score: dose adjustments are common but not always sufficient to assure sustained benefit","volume":"63","author":"Sidiropoulos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0195","first-page":"1538","article-title":"Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis","volume":"31","author":"Stern","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2019.102398_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0205","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102398_bb0210","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from STURE registry showing that switching tumour necrosis factor alpha blockers can make sense","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0215","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and antiinfliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2019.102398_bb0225","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-\u03b1 biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2019.102398_bb0230","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies \u2013 effects on treatment and immunogenicity","volume":"7","author":"Schie","year":"2015","journal-title":"Mabs"},{"key":"10.1016\/j.autrev.2019.102398_bb0235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with immunogenicity of biologicals: assessment and clinical relevance","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2019.102398_bb0240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0245","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0250","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0255","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.24709","article-title":"Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms","volume":"60","author":"Bartelds","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0260","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immungenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102398_bb0265","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0270","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patient with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastrenterol"},{"key":"10.1016\/j.autrev.2019.102398_bb0275","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study","volume":"51","author":"Weiblatt","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2019.102398_bb0280","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0285","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"57 Suppl 7","key":"10.1016\/j.autrev.2019.102398_bb0290","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/rheumatology\/key209","article-title":"The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference","volume":"57","author":"Conti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102398_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.autrev.2019.102398_bb0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/08916934.2014.897333","article-title":"Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review","volume":"47","author":"Sozzani","year":"2014","journal-title":"Autoimmunity."},{"key":"10.1016\/j.autrev.2019.102398_bb0305","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.102398_bb0310","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102398_bb0315","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102398_bb0320","first-page":"390","article-title":"Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences","volume":"31","author":"Favalli","year":"2017","journal-title":"Clin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:15:26Z","timestamp":1761599726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1568997219302058"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102398","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102398"}}